CasBio
Latest round
- Seed
Last raised
- Apr 2024
Total raised
- Undisclosed
Investors
- 1
About CasBio
, dba CasBio, is a biotechnology company that focuses on the development of gene editing therapies. The founder and CEO, Yanming Guan has worked at Calimmune and Rampart Bioscience. The company is committed to the research and development of gene editing technology. It owns alphaCas®, an ultra-compact gene editor, a macro-genome-based gene editor mining platform, and can engineer ultra-compact gene editors as well as target screening and pipeline development. The gene editor is suitable for nonviral vectors and virus delivery platforms, and its developed pipeline has covered liver-targeted and non-liver-targeted directions. The company generates revenue by providing gene editors.
Who invested in CasBio
1 investor across 1 round
See all investors in CasBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Apr 16, 2024
Amount
Undisclosed
Investors
Questions about CasBio
Who invested in CasBio?
CasBio has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CasBio raised?
CasBio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did CasBio last raise money?
CasBio's most recent round on record is a Seed, in Apr 2024.
What does CasBio do?
, dba CasBio, is a biotechnology company that focuses on the development of gene editing therapies.
Where is CasBio headquartered?
CasBio is headquartered in Shanghai, China.
Which VCs invest in companies like CasBio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at CasBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like CasBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.